These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 33045117)

  • 1. Axillary management for patients with breast cancer after neoadjuvant chemotherapy: Results of a survey among Brazilian breast surgeons.
    Frasson AL; Resende HM; Lichtenfels M; Barbosa F; de Souza ABA; Miranda I; Falcone AB
    J Surg Oncol; 2020 Nov; 122(6):1247-1251. PubMed ID: 33045117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary staging and management of cN + breast cancer patients treated with neoadjuvant chemotherapy: results of a survey among breast cancer surgeons in Spain.
    Munoz P; Corral S; Martínez-Regueira F; Paz A; Muñoz-Madero V; Mena A; Cabañas J; Rivas S
    Clin Transl Oncol; 2023 May; 25(5):1463-1471. PubMed ID: 36586064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary Axillary Surgical Management in Patients with Pathologically Node Positive Disease After Neoadjuvant Chemotherapy: A Survey of Members of the American Society of Breast Surgeons.
    Weiss A; Colugnati F; Mitchell M; Li Y; Marin C; Gergelis KR; O'Sullivan CC; Boughey JC
    Ann Surg Oncol; 2024 Oct; 31(11):7362-7371. PubMed ID: 38976157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice.
    Lee SB; Yu JH; Park H; Kim HJ; Park SH; Chae BJ; Youn HJ; Jung SY; Kim EK; Jung YS; Son BH
    Asian J Surg; 2019 Jan; 42(1):314-319. PubMed ID: 30049563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With Breast Cancer and Positive Axillary Lymph Nodes.
    Cipolla C; Lupo S; Grassi N; Battaglia MC; Mesi C; Scandurra G; Gebbia V; Valerio MR
    Anticancer Res; 2024 May; 44(5):2047-2053. PubMed ID: 38677748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
    Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
    Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
    Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
    Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of targeted axillary dissection for de-escalation of surgical treatment after neoadjuvant chemotherapy in breast cancer.
    Aragón-Sánchez S; Ciruelos-Gil E; López-Marín L; Galindo A; Tabuenca-Mateos MJ; Jiménez-Arranz S; Colmenero-Hernández M; Oliver-Pérez MR
    Surg Oncol; 2022 Sep; 44():101823. PubMed ID: 36041377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Normalization in axillary lymph node management after neoadjuvant therapy for breast cancer].
    Wu D; Liu SY; Amina M; Fan ZM
    Zhonghua Wai Ke Za Zhi; 2019 Feb; 57(2):97-101. PubMed ID: 30704211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.
    Mariscal Martínez A; Vives Roselló I; Salazar Gómez A; Catanese A; Pérez Molina M; Solà Suarez M; Pascual Miguel I; Blay Aulina L; Ríos Gozálvez C; Julián Ibáñez JF; Rodríguez Martínez P; Martínez Román S; Margelí Vila M; Luna Tomás MA
    Surg Oncol; 2021 Mar; 36():28-33. PubMed ID: 33285433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience.
    Zhang GC; Liao N; Guo ZB; Qian XK; Ren CY; Yao M; Li XR; Wang K; Zu J
    Clin Transl Oncol; 2013 Jan; 15(1):79-84. PubMed ID: 22926944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel node biopsy after neoadjuvant chemotherapy in cytologically proven node-positive breast cancer.
    Yagata H; Yamauchi H; Tsugawa K; Hayashi N; Yoshida A; Kajiura Y; In R; Matsuda N; Nakamura S
    Clin Breast Cancer; 2013 Dec; 13(6):471-7. PubMed ID: 24267732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy.
    Chun JW; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
    Sci Rep; 2021 Apr; 11(1):9056. PubMed ID: 33907236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy.
    Brabender D; Ballard A; Kim S; Hovanessian-Larsen L; Sener SF
    Breast Cancer Res Treat; 2024 Aug; 206(3):595-602. PubMed ID: 38700572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of the Axilla After Neoadjuvant Chemotherapy: Can Axillary Needle Biopsy Replace Sentinel Node Biopsy?
    Yildirim E; Basim P; Ucar N; Bektas S; Iscen K; Karci E; Ozdemir AA
    In Vivo; 2024; 38(5):2523-2530. PubMed ID: 39187354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower lymph node yield in axillary lymph node dissection specimens in breast cancer patients receiving neoadjuvant chemotherapy: Quality concern or treatment effect?
    Ozao-Choy J; Moazzez A; Dauphine C
    Breast J; 2021 Dec; 27(12):851-856. PubMed ID: 34877726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.